Response to Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806-812.

Autor: Mizokami-Stout KR; Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI kmizokam@med.umich.edu., Li Z; Jaeb Center for Health Research, Tampa, FL., Foster N; Jaeb Center for Health Research, Tampa, FL., Ang L; Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI., Pop-Busui R

Publikováno v: Diabetes care [Diabetes Care] 2020 Sep; Vol. 43 (9), pp. e114-e115.

AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice.

Autor: Choi VW; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Bigelow CE; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., McGee TL; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Gujar AN; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Li H; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Hanks SM; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Vrouvlianis J; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Maker M; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Leehy B; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Zhang Y; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Aranda J; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Bounoutas G; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Demirs JT; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Yang J; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Ornberg R; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Fort Worth, Texas, USA., Wang Y; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Fort Worth, Texas, USA., Martin W; Preclinical Safety, Alcon , Fort Worth, Texas, USA., Stout KR; Preclinical Safety, Alcon , Fort Worth, Texas, USA., Argentieri G; Preclinical Safety, Novartis Institutes for BioMedical Research , East Hanover, New Jersey, USA., Grosenstein P; Preclinical Safety, Novartis Institutes for BioMedical Research , East Hanover, New Jersey, USA., Diaz D; Preclinical Safety, Novartis Institutes for BioMedical Research , East Hanover, New Jersey, USA., Turner O; Preclinical Safety, Novartis Institutes for BioMedical Research , East Hanover, New Jersey, USA., Jaffee BD; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Police SR; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA., Dryja TP; Ophthalmology Disease Area, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts, USA.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2015 Jul 08; Vol. 2, pp. 15022. Date of Electronic Publication: 2015 Jul 08 (Print Publication: 2015).